1. Home
  2. NUVL vs ENS Comparison

NUVL vs ENS Comparison

Compare NUVL & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$123.40

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Logo EnerSys

ENS

EnerSys

HOLD

Current Price

$221.10

Market Cap

8.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
ENS
Founded
2017
1991
Country
United States
United States
Employees
N/A
9200
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
8.5B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
NUVL
ENS
Price
$123.40
$221.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
3
Target Price
$134.75
$193.00
AVG Volume (30 Days)
2.5M
425.1K
Earning Date
05-08-2026
05-20-2026
Dividend Yield
N/A
0.51%
EPS Growth
N/A
N/A
EPS
N/A
7.70
Revenue
N/A
$216,125,000.00
Revenue This Year
N/A
$4.49
Revenue Next Year
$1,239.49
$3.41
P/E Ratio
N/A
$29.42
Revenue Growth
N/A
15.85
52 Week Low
$71.14
$82.45
52 Week High
$123.62
$244.30

Technical Indicators

Market Signals
Indicator
NUVL
ENS
Relative Strength Index (RSI) 66.60 46.46
Support Level $97.71 $216.71
Resistance Level N/A $244.30
Average True Range (ATR) 4.37 9.79
MACD 1.97 -2.58
Stochastic Oscillator 99.39 12.59

Price Performance

Historical Comparison
NUVL
ENS

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About ENS EnerSys

EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, New Ventures, and Specialty.

Share on Social Networks: